Gripex Hot 650 mg/50 mg/10 mg powder for oral solution Bulgarien - bulgarsk - Изпълнителна агенция по лекарствата

gripex hot 650 mg/50 mg/10 mg powder for oral solution

us pharmacia sp.z.o.o. - Парацетамол, аскорбинова киселина, Фенилэфрин - 650 mg/50 mg/10 mg powder for oral solution

Paracetamol Adipharm 500 mg tablets  Bulgarien - bulgarsk - Изпълнителна агенция по лекарствата

paracetamol adipharm 500 mg tablets 

Адифарм ЕАД - Парацетамол - 500 mg tablets 

Influbene 1 000 mg/12,2 mg powder for oral solution Bulgarien - bulgarsk - Изпълнителна агенция по лекарствата

influbene 1 000 mg/12,2 mg powder for oral solution

Тева Фармасютикълс България ЕООД - Парацетамол - 1 000 mg/12,2 mg powder for oral solution

Paracetamol Inbiotech 500 mg tablets  Bulgarien - bulgarsk - Изпълнителна агенция по лекарствата

paracetamol inbiotech 500 mg tablets 

ИНБИОТЕХ ООД - Парацетамол - 500 mg tablets 

Onpattro Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

onpattro

alnylam netherlands b.v. - patisiran натрий - Амилоидоза, Фамилна - Други лекарства в нервната система - onpattro е показан за лечение на наследствени транстиретина-посредничанного амилоидоза (hattr амилоидоза) при възрастни пациенти с 1 етап 2 етап полиневропатия.

Kymriah Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

kymriah

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - Други антинеопластични средства - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Yescarta Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

yescarta

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Антинеопластични средства - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

PRACETAM 200 mg/g powder for use in drinking water for pigs 200 mg/g Bulgarien - bulgarsk - БАБХ (Българска агенция по безопасност на храните)

pracetam 200 mg/g powder for use in drinking water for pigs 200 mg/g

Сева Анимал Хелт България ЕООД - Парацетамол - прах за прилагане във вода за пиене - 200 mg/g - прасета

PRACETAM 200 mg/ml solution for use in drinking water for pigs 200 mg/ml Bulgarien - bulgarsk - БАБХ (Българска агенция по безопасност на храните)

pracetam 200 mg/ml solution for use in drinking water for pigs 200 mg/ml

Сева Анимал Хелт България ЕООД - Парацетамол - разтвор за прилагане във вода за пиене - 200 mg/ml - прасета

Tecartus Den Europæiske Union - bulgarsk - EMA (European Medicines Agency)

tecartus

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - Лимфом, мантел-клетка - Антинеопластични средства - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).